zintick
KIDS Orthopediatrics+29.3%Stock moveEarnings and guidance

OrthoPediatrics Stock Jumps 29% After Third-Quarter Results and Raised 2026 Revenue Guidance

The company reported record third-quarter revenue of $72.7 million, up 19%, and lifted its full-year revenue outlook to $270.0 million to $273.0 million.

By Zintick Team · Editor: Kratik Mehta
Published

KIDS · Oct. 28, 2026
+29.3%
the session's move

Key points

  • Shares rose 29.3% on Oct. 28 after OrthoPediatrics reported record Q3 revenue and raised 2026 guidance
  • Q3 revenue $72.7 million, up 19% year over year
  • 2026 revenue guidance raised to $270.0 million to $273.0 million
  • Q3 net loss narrowed to $5.9 million from $11.8 million

OrthoPediatrics Corp. (Nasdaq: KIDS) shares rose 29.3% on Wednesday, Oct. 28, 2026, closing at $30.80 against a previous close of $23.82. The S&P 500 ETF (SPY) rose 0.34% over the same session, and volume ran at about 8.7 times normal.

The move followed the company's third-quarter results, released in an 8-K filed the previous evening, Oct. 27, at 4:07 p.m. ET. The press release attached to that filing reported record third-quarter revenue of $72.7 million, up 19% from $61.2 million a year earlier. Trauma and Deformity revenue rose 19% and Scoliosis rose 18%. Gross margin held at 74%.

Guidance raised

The company increased its full-year 2026 revenue guidance to $270.0 million to $273.0 million, from a prior range of $265.0 million to $269.0 million. That represents growth of 14% to 16% over 2025. It reiterated expectations for adjusted EBITDA of about $25.0 million and breakeven free cash flow in 2026.

Profitability and losses

Third-quarter net loss was $5.9 million, or $0.25 per share, compared with a net loss of $11.8 million, or $0.50 per share, a year earlier, so the loss narrowed. Adjusted EBITDA was $6.9 million, against $6.2 million in the prior-year quarter. Free cash flow was $1.6 million, compared with a use of $3.4 million a year earlier.

Cash, short-term investments and restricted cash totaled $44.9 million at Sept. 30, 2026, down from $62.9 million at Dec. 31, 2025.

Analyst view

BTIG kept its Buy rating on the stock and raised its price target to $30.00 from $29.00 before the open on Oct. 28.

The company's filings did not state a single reason for the size of the share-price reaction beyond the results and guidance above.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

KIDS page →

Filings, figures and price history are on the Orthopediatrics page.